सभी अध्ययन
आमंत्रण द्वारा नामांकनप्रेक्षणीय

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

This important study is designed for adult men in the UK living with haemophilia B. It's a long-term follow-up for those who previously took part in earlier studies (CSL222_2001 or CSL222_3001) where they received a gene therapy treatment called etranacogene dezaparvovec. The main purpose is to see how safe the treatment remains over many years and how effective it continues to be in managing their haemophilia B. By carefully monitoring participants, researchers hope to gain a better understanding of the lasting effects of this innovative treatment, which could ultimately help improve future care for people with this condition.

एक नजर में

स्थिति
आमंत्रण द्वारा नामांकन
प्रायोजक
CSL Behring
नामांकन लक्ष्य
56
प्रारंभ
30 अगस्त 2023
अनुमानित पूर्णता
23 Mar 2035

यह अध्ययन किस बारे में है?

This study is a follow-up for adult men with haemophilia B who have already received a special gene therapy. Haemophilia B is a lifelong bleeding disorder where your blood doesn't clot properly due to a missing or faulty ‘Factor IX’ protein. Gene therapy like etranacogene dezaparvovec aims to provide instructions to your body to make this missing protein, potentially reducing bleeding episodes.

This particular study isn't offering new treatment; instead, it's looking at the long-term effects for people who have already had this gene therapy. Researchers want to understand if the treatment continues to be safe over many years and if it keeps working effectively to help manage haemophilia B. This is really important because gene therapies are relatively new, and understanding their long-term impact helps doctors and scientists make informed decisions about their wider use.

By carefully checking on the health and progress of these participants, the study contributes valuable information. It helps build a bigger picture of how this treatment works in the real world, beyond the initial trials. This knowledge is crucial for advancing our understanding of haemophilia B and developing even better therapies in the future.

मुख्य निष्कर्ष

  • This is a long-term follow-up study for men with haemophilia B.
  • Participants have already received a gene therapy called etranacogene dezaparvovec.
  • The study aims to understand the long-term safety and effectiveness of the treatment.
  • No new medication is given; it involves regular monitoring and health checks.
  • Your participation helps improve future care for haemophilia B patients.

कौन पात्र हो सकता है?

To be considered for this study, you must be an adult male who previously participated in one of the original treatment trials for etranacogene dezaparvovec – specifically, study CSL222_2001 or study CSL222_3001.

Additionally, you must have either fully completed your participation in one of those earlier studies, or at least five years must have passed since you received the etranacogene dezaparvovec gene therapy in one of those trials.

There are no other specific reasons listed that would prevent you from joining this follow-up study, provided you meet the criteria above.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. I am an adult male (aged 18 or over).
  2. I was previously treated with etranacogene dezaparvovec (CSL222) in study CSL222_2001 or CSL222_3001.
  3. I completed my participation in one of those earlier studies.
  4. OR at least 5 years have passed since I received the CSL222 treatment.
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part, you'll be regularly monitored by a medical team. This will involve scheduled visits to the clinic where you'll have various health checks. These typically include blood tests to measure your Factor IX levels and check your general health, physical examinations, and questions about any bleeding episodes or your overall well-being. You won't be receiving new medication as part of this study; it's purely for observation. The total duration of your participation will depend on how long ago you received the gene therapy, as the study aims to track participants for many years after their initial treatment.

संभावित जोखिम और लाभ

Participating in this study offers a potential benefit of ongoing, close medical supervision of your health, particularly regarding your haemophilia B and the effects of the gene therapy you received. You would also be contributing valuable information that could help others living with haemophilia B in the future. As you have already received the treatment, the direct risks from the treatment itself are not new, but any long-term monitoring study involves regular clinic visits, which can be time-consuming, and blood tests, which carry minimal risks like bruising. You are free to withdraw from the study at any time without needing to give a reason, and this will not affect your usual medical care.

स्थान (28)

  • 10-15 Phoenix Childrens Hospital
    सत्यापित पोस्टकोड
    फीनिक्स, संयुक्त राज्य अमेरिका
  • 10-14 Arkansas Children's Hospital - Pharmacology
    सत्यापित पोस्टकोड
    लिटिल रॉक, संयुक्त राज्य अमेरिका
  • 10-22 Orthopaedic Institute for Children
    सत्यापित पोस्टकोड
    लॉस एंजेलेस, संयुक्त राज्य अमेरिका
  • 10-21 Children's Hospital of Los Angeles
    सत्यापित पोस्टकोड
    लॉस एंजेलेस, संयुक्त राज्य अमेरिका
  • 10-63 UC Davis Medical Center
    सत्यापित पोस्टकोड
    सैक्रामेंटो, संयुक्त राज्य अमेरिका
  • 10-12 University of California, San Diego (UCSD)
    सत्यापित पोस्टकोड
    सैन डिएगो, संयुक्त राज्य अमेरिका
  • 10-25 University of Colorado Denver
    सत्यापित पोस्टकोड
    ऑरोरा, संयुक्त राज्य अमेरिका
  • 10-19 University of South Florida
    सत्यापित पोस्टकोड
    टाम्पा, संयुक्त राज्य अमेरिका
  • 10-10 University of Michigan Medical Center
    सत्यापित पोस्टकोड
    ऐन आर्बर, संयुक्त राज्य अमेरिका
  • 10-16 University of North Carolina at Chapel Hill
    सत्यापित पोस्टकोड
    चैपल हिल, संयुक्त राज्य अमेरिका
  • 10-18 Oregon Health & Science University
    सत्यापित पोस्टकोड
    पोर्टलैंड, संयुक्त राज्य अमेरिका
  • 10-20 Vanderbilt University Medical Center
    सत्यापित पोस्टकोड
    नैशविल, संयुक्त राज्य अमेरिका

सामान्य प्रश्न

What is haemophilia B?

Haemophilia B is an inherited bleeding disorder where your blood doesn't clot properly due to a missing or faulty Factor IX protein, leading to prolonged bleeding.

What is etranacogene dezaparvovec?

It's a gene therapy treatment that aims to help your body produce the missing Factor IX protein, which can reduce bleeding episodes in people with haemophilia B.

Am I receiving new treatment in this study?

No, this study is a follow-up. You won't receive new treatment; it's for monitoring those who previously had the gene therapy.

मुझे अध्ययन में कितने समय तक रहना होगा?

The study aims for long-term follow-up; the duration for you will depend on when you received your initial gene therapy treatment in the parent studies.

What is the purpose of this long-term study?

The main purpose is to understand the long-term safety and effectiveness of etranacogene dezaparvovec gene therapy for men with haemophilia B.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "Long-term Follow-up Study of Male Adults With Hemophilia B P…यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.